Additionally, ALDH2 expression levels in BRAF-mutated metastatic melanoma cells influence cell sensitivity to BRAF and MEK inhibitors, with low ALDH2 expression associated with both intrinsic and acquired resistance. This evidence concerns the gene MAP2K7 and melanoma.